15
Global Research of the Impact of Dermatological Diseases (GRIDD) June 2017 1

Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

  • Upload
    others

  • View
    3

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

Global Research of the Impact of

Dermatological Diseases (GRIDD)

June 2017

1

Page 2: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

Who do we represent?

Nearly 60 Patient Organizations and growing…

23 Countries 25 Disease Areas

2

2 3 2 14 4 6

3 4 4 38

14 3 2 22

5 7 812

16

22 2529

33 36

4445

49 52 55 57

0

10

20

30

40

50

60

70

Nov-15 Jan-16 Feb-1 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17

Monthly Cumulative

Acne & Rosacea2% ALL / many

7%Alopecia

4%Burns

2%

Eczema6%

Nevus / BCCNS11%

Other6%

Psoriasis11%

RARE Diseases*22%

Skin Cancer4%

Vitiligo13%

XP6%

E.B.4%

HS2%

Page 3: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

3

Page 4: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

The Goal: Elevate the importance of

dermatology

A rising tide lifts all boats.4

Page 5: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

Challenges for Dermatology Patients

5

• Dermatological diseases are largely considered to be of low impact. In a great many cases, this is simply false.

• Dermatological diseases are both stigmatized and minimized

Dispel Myths

• Patient organizations are ill equipped...

• Qualitative information gathered by patient leaders doesn’t fit quantitative decision-making rubric.

Quantify Impact?

Page 6: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

Opportunities

The unique opportunity at this

moment in time:

•There is a growing movement

worldwide to include “the patient

voice” in healthcare policy decision-

making.

•If people living with the disease can

bring information to the table using the

lexicon of decision-makers (i.e. data),

then their perspective on the lived

experience of the condition can

inform healthcare decisions. 6

Page 7: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

IADPO’s Response

Global Research on the Impact of Dermatological

Diseases (GRIDD)

Objective: Using a unique approach, capture the voice of

the people and their experience living with the condition in

their own skin and to bring those perspectives to the

attention of those making decisions on our behalves.

7

Page 8: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

GRIDD

8

Tool

▪Creation of the Global Research: Impact on Patients (GRIP) tool which establishes the key questions to be asked from the patients’ perspectives to fully describe the burden of disease from their perspective.

Instrument

▪Survey using aggregated questions on the impact of the dermatological condition on the lives of patients and their family members as defined by the GRIP tool, including impact on: psycho-social impacts, life trajectory, Work, psychological status, social environment, Family leisure time.

Data

•Patient experience data which can be reported by country and disease•Verifiable data which tells a compelling story about dermatological diseases•Support data-driven patient involvement and advocacy in decisions about research spending, drug approvals and specialist funding

How GRIDD differs from existing research:

Page 9: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

GRIDD

•What is Global Research on the Impact of Dermatological Diseases (GRIDD)?

• Ground-breaking patient-led impact research

• Questions in Instrument developed by patients, not researchers

• Patient experience data which can be analyzed by country and disease

•What will this change?

• Verifiable data which tells a compelling story about dermatological diseases

• Increase credibility for data-driven patient involvement and advocacy in decisions about research spending, drug approvals and specialist funding

9

Page 10: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

GRIDD

•The power of data:

• Patient experience data

• Directly from patients

• Helps under resourced patient organizations

• Supports patient involvement in decisions

about drug approvals

• Sharper tool for patient advocacy

• Can be used in conjunction with clinical outcomes research

10

Page 11: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

GRIDD

Why GRIDD is important for Dermatology worldwide:

1. Patient–derived measures of impacts to change

perceptions

2. Improving advocacy (all levels) to decision-makers

3. Validating existing PROMS and DLQI data

4. Changing the DALY ranking

5. Positive reputational benefits for all organizations and

physicians and researchers involved

11

Page 12: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

GRIDD: Outcomes

✓ Greater understanding and respect for dermatological diseases

✓ Global Research of Impact on Patients (GRIP) tool allows patients living with dermatological diseases to co-create questions

✓ Unique measurement instrument

✓ Global Report on the Impact of Dermatological Diseases with a breakdown by country, region and disease

✓ Tools that empower dermatological patient leaders, and give additional support to all stakeholders for advocacy for better access to care and treatment

12

Page 13: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

Togther we will raise the profile for

dermatology

1. Send us/Give me contact information for all dermatology patient organizations in your country incl. pemphigus /pemphigoid

2. Connect us with your patients who are keen to start a support or advocacy group.

3. Agree to sign up to be a physician supporter. Give me your card or tell Marc Yale.

13

Page 14: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

14

Calling all patient leaders…

Register Today! Travel grants available. www.globalskin.org/conference

Page 15: Global Research of the Impact of Dermatological Diseases (GRIDD) · 2017. 6. 16. · Skin Cancer 4% Vitiligo 13% XP 6% E.B. 4% HS 2%. 3. ... Myths •Patient organizations are ill

Thank you

Christine Janus, CEO

[email protected]

15